Biosion

Latest News

Biosion Novel Antibody Therapies to be Featured at SITC 2023 (Society for Immunotherapy of Cancer)

Release time:

2023-10-23 17:04:00

NEWARK, U.S.A. and NANJING, China — Oct 20, 2023, Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced two abstracts have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego.

“We look forward to presenting the posters for BSI-510 and BSI-706, our first-in-class anti-Siglec-15ⅹGM-CSF bispecific fusion molecule and novel anti-CLDN18.2 monoclonal antibody, respectively. BSI-510 and BSI-706 demonstrate favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies.” said Hugh M. Davis, Ph.D., Chief Business & Development Officer, and President of Biosion USA, Inc..

Title: Antibody-Drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors

Poster Number: 1151

Title: BSI-510, a Novel Bispecific Molecule Combining an Anti-Siglec-15 Antibody with Cytokine GM-CSF for Enhanced Antitumor Efficacy

Poster Number:1176

Additionally, Biosion’s partner, Pyxis Oncology, will also be presenting a poster on the clinical advancement of PYX-106 (BSI-060T) ,which is an investigational, fully human, anti-Siglec-15 monoclonal antibody that binds to human Siglec-15 with high affinity and cross-reacts to cynomolgus monkey, rat, and mouse Siglec-15. PYX-106 potently reverses Siglec-15-mediated suppression of CD4+ and CD8+ proliferation and induces IFN-gamma secretion in an ex vivo model.

Title: Pyxis Oncology- First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors

Poster Number: 756

About Biosion, Inc.

Biosion is a global, clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer ® HT endocytosis platform, and Flexibody ® bispecific platform. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and atopic dermatitis, with another 4 partnered assets in phase-I/II. Biosion and partners have plans to progress the immune-oncology and antibody drug conjugate-based portfolio into clinical trials for oncology indications over the next year. Biosion has operations in the US, Australia, and China. For more information, please visit www.Biosion.com.

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology’s antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.

Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)

Biosion Announces Two Poster Presentations of Novel Antibody at SITC 2023